Our Investor Proposition

Unlocking value for our shareholders

Our growing commercial business is funding Valneva’s exciting R&D pipeline

Stock Information

€3,00 +1,35% Last update: August 19, 2019 at 13:25 CET Stock Price

“We have the only clinical-stage vaccine program against Lyme disease worldwide.”

Valneva's CEO Thomas Lingelbach comments on Group Strategy

Valneva R&D Investor Day

Valneva held its R&D Investor Day on July 9, 2019 in New York.

Upcoming Events

October 28, 2019

World Vaccine Congress Europe

October 31, 2019

9M 2019 Interim Results

2019 Half-Year Report

Contact

Investor Relations Team

Campus Bio-Ouest
6, Rue Alain Bombard
44800 Saint-Herblain, France

T: +33 2 28 07 37 10 investors@valneva.com

Subscribe to Valneva News

Submit

Press Releases

August 1, 2019

Valneva Reports H1 2019 Results Marked by Strong Operational Performance and Major Corporate Progress

July 29, 2019

Valneva Announces Formation of Scientific Advisory Board

July 25, 2019

CEPI awards up to US$23.4 million to Valneva for late-stage development of a single-dose chikungunya vaccine

View More